KARPAS 353 Human B-cell Leukaemia cell line

KARPAS 353 Human B-cell Leukaemia cell line useful in oncology research, developed at the University of Cambridge.

Technology No. KAR-6356-19

Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. We have partnered with ECACC (The European Collection of Cell Cultures; a Public Health England Culture Collection) to manage distribution of the majority of these cells on our behalf. Enquires to either organisation are welcomed.

References (1)
1. E Nacheva, M J Dyer, P Fischer, G Stranks, J M Heward, R E Marcus, C Grace, A Karpas (05-01-1993), C-MYC translocations in de novo B-cell lineage acute leukemias with t(14;18)(cell lines Karpas 231 and 353), blood, 82, 231-240
Supporting documents (1)

Product brochure

KARPAS 353 Human B-cell Leukaemia cell line.pdf

DOWNLOAD

Additional files may be available once you've completed the transaction for this product. If you've already done so, please log into your account and visit My account / Downloads section to view them.

Internal Research Licence - 1 Year

1-year non-exclusive licence agreement for use of the Karpas 353 Cell Line for internal research only.

Term: 12 months

Price on approval

Order now

Sign up to our newsletter

If you would like to keep up to date with the latest opportunities, please sign up to our newsletter.